Simvastatin in patients with progressive multiple sclerosis

Lancet. 2014 Sep 13;384(9947):952. doi: 10.1016/S0140-6736(14)61621-4.

Authors

Gavin Giovannoni¹, David Baker², Klaus Schmierer²

Affiliations

¹ Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London E1 2AT, UK. Electronic address: g.giovannoni@qmul.ac.uk.
² Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London E1 2AT, UK.

PMID: 25220965
DOI: 10.1016/S0140-6736(14)61621-4

No abstract available

Publication types

Letter
Comment

MeSH terms

Brain / pathology*
Disabled Persons*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Male
Multiple Sclerosis, Chronic Progressive / drug therapy*
Simvastatin / administration & dosage*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin